Engineered immunostimulatory bacterial strains and uses thereof

An immunostimulatory, immune cell technology, applied in the direction of blood/immune system cells, bacteria, anti-animal/human immunoglobulin, etc.
CN112673092APending Publication Date: 2021-04-16阿克蒂姆治疗有限公司
116 Cites 10 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
阿克蒂姆治疗有限公司
Publication Date
2021-04-16

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and / or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella or modification of the genes so that functional flagella are not produced, and / or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin- and / or pagP -. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd -, purI - and msbB -. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and / or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment or tumor-resident immune cells and / or induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related applications

[0002] This application claims International Patent Application No. PCT / US2018 / 041713 filed on July 11, 2018 and published as WO 2019 / 014398 on January 17, 2019 and filed on July 11, 2018 and published on January 2019 The benefit of priority to co-pending US Patent Application Serial No. 16 / 033,187, published on the 17th as US Publication No. U.S. 2019 / 0017050 Al, each by applicant Actym Therapeutics, Inc., inventors Christopher D. Thanos, LauraHix Glickman and Justin Skoble; and each titled "ENGINEERED IMMUNO STIMULATORY BACTERIAL STRAINS AND USES THEREOF".

[0003] Also claims the benefit of priority to U.S. Provisional Application Serial No. 62 / 789,983, filed January 08, 2019, applicant Actym Therapeutics, Inc., inventors Christopher D. Thanos, Laura Hix Glickman, Justin Skoble, and Alexandre Charles Michel Iannello and entitled "ENGINEERED IMMUNO STIMULATORY BACTERIAL STRAINS AND USESTHEREOF". Also claims priority of U.S. Provisional Applicatio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More